Retropubic radical prostatectomy: The results

Abstract

The increase in prostate-specific antigen (PSA) screening, combined with a reduction in the threshold of indications for prostate biopsy and the greater number of samples taken, has contributed to an increase in the diagnosis of prostate cancer. This has led to earlier detection, to downstaging of the disease, and to an increase in the number of patients presenting with clinically organ-confined disease. This, in turn, has led to an increase in the number of candidates for radical prostatectomy (RP). RP is the standard treatment for patients with an organ-confined prostate cancer and a life expectancy of more than 10 years who accept treatment-related complications [1].